The Genetics of Very Early Onset Alzheimer Disease
Abstract
Objective This study was undertaken to clarify the genetics of very early onset Alzheimer disease (VEOAD), defined as AD beginning before age 35. Background Early onset AD (EOAD) is defined by onset of symptoms before age 65, and affected individuals may harbor a mutation in presenilin 1 (PSEN1), presenilin 2 (PSEN2), or amyloid precursor protein. VEOAD is exceedingly rare, and PSEN1 mutations have been implicated. We encountered a man with phenotypic frontotemporal dementia beginning at age 32 and a strong family history of an autosomal dominant dementia who was found at autopsy to have AD. Methods Histologic and genetic analyses of the patient's brain were undertaken, and a review of all published VEOAD cases was performed. Results Histologic findings were diagnostic of advanced stage AD. Genetic evaluation of brain tissue identified an intronic PSEN1 polymorphism; no known pathogenic mutation was found. Literature review (1934 to 2007) disclosed 101 cases of VEOAD; the youngest age of dementia onset was 24 years. In all cases in which definitive genetic analysis was available, either a PSEN1 mutation or linkage to chromosome 14 was found. Conclusions VEOAD can present with atypical clinical features, including findings suggestive of frontotemporal dementia. All reported cases of VEOAD with conclusive genetic analysis seem to be associated with PSEN1 mutations. Genetic testing in adults younger than 35 with dementia can identify the genetic defect and assist in diagnosis an…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Autosomal-dominant AD is caused by mutations in APP and PSEN1 and PSEN2 genes.
“Autosomal-dominant AD (ADAD) is an inherited form of AD caused by mutations in amyloid precursor protein ( APP ) and presenilin-1 and 2 ( PSEN1; PSEN2 ) genes (49, 177, 303, 304, 580).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [177]
Some PSEN1 mutations lead to very early onset ADAD (<35 years of age).
“Some PSEN1 mutations lead to very early onset ADAD ( < 35 yr of age) (177, 304).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [177]
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
Kumar-Singh, S. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.18.2589 · Cited by 158 · see citing works
Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease
Beck, J. A. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh134 · Cited by 102 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works
Early onset dementia: clinical and social aspects
Werner, P., Stein-Shvachman, I., & Korczyn, A. D. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009223 · Cited by 122 · see citing works
- Authors
- Filley, C. M., Rollins, Y. D., Alan Anderson, C., Arciniegas, D. B., Howard, K. L., Murrell, J. R., Boyer, P. J., Kleinschmidt-DeMasters, B. K., & Ghetti, B.
- Affiliations
- Denver VA Medical Center (US)
- Neurology, Inc (US)
- Indiana University Indianapolis (US)
- Corresponding author
- Filley, Christopher M.
- Rollins, Yvonne D.
- Arciniegas, David B.
- Howard, Katherine L.
- Venue
- Cognitive and Behavioral Neurology
- Published
- 2007-09
- Volume
- 20
- Issue
- 3
- Pages
- 149-156
- ISSN
- 1543-3633 (ISSN-L)
- OpenAlex
- W2047265153
- Cited by
- 53
- References
- 3
- Citations by year
- 2026: 3 · 2023: 3 · 2022: 2 · 2020: 2 · 2019: 1 · 2018: 4 · 2017: 1 · 2016: 3 · 2015: 4 · 2014: 5 · 2013: 4 · 2012: 1
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cognitive and Behavioral Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (AG 10133, P30AG010133)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- presenilin 1, PSEN1 mutations, frontotemporal dementia, amyloid precursor protein, atypical presentation, genetic testing, family counseling
- MeSH terms
- Adult, Alzheimer Disease, Atrophy, Brain, Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 21, Humans, Introns, Male, Neuropsychological Tests, Polymorphism, Genetic, Neurofibrillary Tangles, Point Mutation, Fatal Outcome, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review